THE ROLE OF LYMPHODISSECTION IN THE TREATMENT OF PATIENTS WITH DISSEMINATED OVARIAN CANCER
- Authors: Nikogosyan S.O.1, Mamajonov H.I1, Levchenko N.E1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: Vol 23, No 2 (2018)
- Pages: 96-101
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/42981
- DOI: https://doi.org/10.18821/1028-9984-2018-23-2-96-101
- ID: 42981
Cite item
Full Text
Abstract
For many years ovarian cancer (OC) has remained the leading cause of mortality from gynecological cancer diseases. The problem of late diagnosis of ovarian cancer remains still unresolved in more than 70% of patients when the diagnosis is established at advanced stages. The standard approach to the treatment of patients is to perform surgical removal of the tumor at the first stage, which often pursues both therapeutic and diagnostic purposes, as it allows performing the disease restaging and assessing its prevalence. To date, the question of the relevance of implementation and the extent of lymph node dissection still remains open. In this regard, in this article, we want to present the available evidence base regarding the use of the performing retroperitoneal lymph node dissection in advanced OC patients.
Full Text
##article.viewOnOriginalSite##About the authors
Seda O. Nikogosyan
N.N. Blokhin National Medical Research Center of Oncology
Email: assay@mail.ru
MD, Ph.D., DSci., leading researcher of the Department of Gynecology of the N.N. Blokhin National Medical Research Center of Oncology, Moscow, 115478, Russian Federation Moscow, 115478, Russian Federation
H. I Mamajonov
N.N. Blokhin National Medical Research Center of OncologyMoscow, 115478, Russian Federation
N. E Levchenko
N.N. Blokhin National Medical Research Center of OncologyMoscow, 115478, Russian Federation
References
- Kaprin A.D., Starinsky V.V., Petrova G.V. Еds. Malignant diseases in Russia in 2015 (morbidity and mortality). Moscow; 2017. (in Russian)/ Каприн А.Д., Старинский В.В., Петрова Г.В. (ред). Злокачественные заболевания в России в 2015 году (заболеваемость и смертность). М.; 2017.
- Howlader N., Noone A.M., Krapcho M. et al. SEER Cancer Sta-tistics Review, 1975-2012, based on November 2014 SEER data submission, posted to the SEER web site. April 2015.
- Тюляндин С.А., Деньгина Н.В., Коломиец Л.А., Морхов К.Ю., Нечушкина В.М., Покатаев И.А., Тюляндина А.С., Урманчеева А.Ф., Хохлова С.В. Практические рекомендации по лекарственному лечению рака яичников/первичного рака брюшины/рака маточных труб. Злокачественные опухоли. 2016; S6: 123-34.
- NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1.2017.
- Chi D.S., Eisenhauer E.L., Zivanovic O. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 2009; 114(1): 26-31. doi: 10.1016/j.ygyno.2009.03.018
- Trimbos J.B., Vergote I., Bolis G. et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J. Natl. Cancer Inst. 2003; 95(2): 113-25. doi: 10.1093/jnci/95.2.113
- Chan J.K., Munro E.G., Cheung M.K., Husain A., Teng N.N. et al. Association of lymphadenectomy and survival in stage I ova-rian cancer patients. Obstet. Gynecol. 2007; 109(1): 12-19.
- Tada H., Teramukai S., Fukushima M., Sasaki H. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC Cancer. 2009; 9: 47. doi: 10.1186/1471-2407-9-47
- Fujita K., Nagano T., Suzuki A., Sakakibara A., Takahashi S. et al. Incidence of postoperative ileus after paraaortic lymph node dissection in patients with malignant gynecologic tumors. Int. J. Clin. Oncol. 2005; 10(3): 187-90. doi: 10.1007/s10147-005-0494-9
- McMahon C.J., Rofsky N.M., Pedrosa I. Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology. 2010; 254(1): 31-46.
- Hartveit E. Attenuated cells in breast stroma: the missing lymphatic system of the breast. Histopathology. 1990; 16(6): 533-43.
- Pepper M.S., Tille J.C., Nisato R., Skobe M. et al. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003; 314(1): 167-77. doi: 10.1007/s00441-003-0748-7
- Nomura H., Tsuda H., Susumu N., Fujii T., Banno K. et al. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2010; 20(3): 341-5. doi: 10.1111/IGC.0b013e3181cf6271
- Powless C.A., Aletti G.D., Bakkum-Gamez J.N., Cliby W.A. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol. Oncol. 2011; 122(3): 536-40. doi: 10.1016/j.ygyno.2011.05.001
- Takeshima N., Hirai Y., Umayahara K., Fujiwara K., Takizawa K. et al. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol. Oncol. 2005; 99(2): 427-31. doi: 10.1016/j.ygyno.2005.06.051
- Pereira A., Magrina J.F., Rey V., Cortes M., Magtibay P.M. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol. Oncol. 2007; 105(3): 604-8. doi: 10.1016/j.ygyno.2007.01.028
- Bogani G., Tagliabue E., Ditto A. et al. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. Gynecol. Oncol. 2017; 147(1): 61-5. doi: 10.1016/j.ygyno.2017.07.139
- Chen S.S., Lee L. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol. Oncol. 1983; 16(1): 95-100. doi: 10.1016/0090-8258(83)90013-6
- Harter P., Gnauert K., Hils R. et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2007; 17(6): 1238-44.
- Burghardt E., Winter R. The effect of chemotherapy on lymph node metastases in ovarian cancer. Baillieres Clin. Obstet. Gy-naecol. 1989; 3(1): 167-71.
- Ayhan A., Gultekin M., Taskiran C., Celik N.Y., Usubutun A. et al. Lymphatic metastasis in epithelial ovarian carcinoma with respect to clinicopathological variables. Gynecol. Oncol. 2005; 97(2): 400-4. doi: 10.1016/j.ygyno.2005.01.038
- Luyckx M., Leblanc E., Filleron T. et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice. Int. J. Gynecol. Cancer. 2012; 22(8): 1337-43. doi: 10.1097/IGC.0b013e31826a3559
- Chang S.J., Bristow R.E., Ryu H.S. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann. Surg. Oncol. 2012; 19(13): 4059-67. doi: 10.1245/s10434-012-2446-8
- Peiretti M., Zanagnolo V., Aletti G.D. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol. Oncol. 2010; 119(2): 259-64. doi: 10.1016/j.ygyno.2010.07.032
- Harter P., Muallem Z.M., Buhrmann C., Lorenz D., Kaub C., Hils R. et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol. Oncol. 2011; 121(3): 615-9. doi: 10.1016/j.ygyno.2011.02.014
- Wimberger P., Lehmann N., Kimming R. et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gy-naekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol. Oncol. 2007; 106(1): 69-74. doi: 10.1016/j.ygyno.2007.02.026
- Eisenkop S.M, Spirtos N.M. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol. Oncol. 2001; 82 (1): 143-9. doi: 10.1006/gyno.2001.6232
- Harter P., Sehouli J., Lorusso D. et al. LION - Lymphadenectomy In Ovarian Neoplasms. A Prospective Randomized Ago Study Group Led Gynecologic Cancer Intergroup Trial. Presented at ASCO 2017 Annual Meeting.
- Panici P.B., Maggioni A., Hacker N. et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J. Natl. Cancer Inst. 2005; 97 (8): 560-6. doi: 10.1093/jnci/dji102
- Chan J.K., Urban R., Hu J.M., Shin J.Y., Husain A. et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients. Br. J. Cancer. 2007; 96 (12): 1817-22.
- du Bois A., Reuss A., Harter P. et al. Potential role of lymph-adenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J. Clin. Oncol. 2010; 28 (10): 1733-9. doi: 10.1200/JCO.2009.25.3617
- Atallah D., Rassy E.E., Chahine G. Is the LION strong enough? Future Oncol. 2017; 13 (21): 1835-7. doi: 10.2217/fon-2017-0292
- Eisenkop S.M., Friedman R.L., Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 1998; 69 (2): 103-8. doi: 10.1006/gyno.1998.4955